Southern Archipelago (A33) H1 2024 earnings summary
Event summary combining transcript, slides, and related documents.
H1 2024 earnings summary
5 Nov, 2026Executive summary
1H2024 revenue fell 13% YoY to S$2.337m, while net profit was S$24k versus a S$516k loss; sterilisation remained the sole revenue-generating segment.
Net current liabilities widened to S$2.279m at 30 June 2024; directors considered going-concern preparation appropriate based on cash-flow forecasts, expected sterilisation cash generation and potential financing.
Financial highlights
Revenue declined to S$2.337m from S$2.696m, mainly due to reduced cobalt activity in sterilisation.
Other gains were S$324k versus S$154k of losses, mainly reflecting a S$307k currency exchange gain; other expenses rose to S$857k, including cobalt-waste disposal fees and duties.
Profit before tax was S$283k versus a S$287k loss; net profit was S$24k versus a S$516k loss, after S$259k income tax expense.
Total comprehensive loss was S$408k versus S$48k, reflecting a S$432k foreign currency translation loss versus a S$468k gain.
Outlook and guidance
Sterilisation is expected to improve in 2H2024 as cobalt rods replaced in late June increase sales capacity; capacity expansion is underway.
Management expects sterilisation to grow and generate positive operating cash flow; forecasts indicate sufficient resources for operations and obligations over the next 12 months.
Funding may include internal resources, shareholder loans, borrowings or capital raising; options under exploration include bank loans and shareholder funding.
Latest events from Southern Archipelago
- Sterilisation recovery continues, but liquidity strains and a covenant breach cloud the outlook.A33
Q3 2026 - Revenue and net profit improved, but liquidity and diversification remain key challenges.A33
H2 2023 - Sterilisation expansion continued as lower revenue, a net loss and tight liquidity shaped FY2024.A33
H2 2024 - Sterilisation growth plans amid a S$566k loss, negative working capital and covenant risk.A33
H1 2025 - Revenue fell 17.8%; upgraded capacity meets a strained balance sheet and recovery test.A33
H2 2025 - Revenue fell 47% amid Indonesian headwinds, with liquidity and covenant risks still acute.A33
Q1 2026 - Sterilisation rebounded in 2Q, but liquidity pressure and a loan covenant breach persist.A33
H1 2026